en · de · es
aod-9604-notes.peptides1004.com › Data › Background And Research Context — Reference Sheet

Background And Research Context — Reference Sheet

By Editorial Desk · published 2026-05-04 · last reviewed 2026-06-02 · Data

anti-doping analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Handling, Analysis, and Quality Control

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Related pages on this site

Regulation and Detection Context

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Reference notes

==== Establishment and growth ==== In the first half of the 1st century AD, acupuncturists began promoting the belief that acupuncture's effectiveness was influenced by the time of day or night, the lunar cycle, and the season. The 'science of the yin-yang cycles' (運氣學 yùn qì xué) was a set of beliefs that curing diseases relied on the alignment of both heavenly (tian) and earthly (di) forces that were attuned to cycles like that of the sun and moon. There were several different belief systems that relied on a number of celestial and earthly bodies or elements that rotated and only became aligned at certain times. According to Needham and Lu, these "arbitrary predictions" were depicted by acupuncturists in complex charts and through a set of special terminology. Acupuncture needles during this period were much thicker than most modern ones and often resulted in infection. Infection is caused by a lack of sterilization, but at that time it was believed to be caused by use of the wrong needle, or needling in the wrong place, or at the wrong time. Later, many needles were heated in boiling water, or in a flame. Sometimes needles were used while they were still hot, creating a cauterizing effect at the injection site. Nine needles were recommended in the Great Compendium of Acupuncture and Moxibustion from 1601, which may have been because of an ancient Chinese belief that nine was a magic number. Other belief systems were based on the idea that the human body operated on a rhythm and acupuncture had to be applied at the right point in the rhythm to be effective.

== Epidemiology == Prevalence of disease in a rigorous meta-analysis in 2017 was 46 patients per million. The earliest published prevalence was in 2000 and put at 5 per million. A 2017 study in Ireland reported 112 per million. It is not believed that the disease prevalence is increasing with time, but rather diagnostics and reporting are improving. Estimates of the mean age of onset range from 61 to 68 years old.

Ganglion tissue is composed of cell bodies, dendrites, and satellite glial cells. Nerves are composed of myelinated and unmyelinated axons, Schwann cells surrounded by connective tissue. The three layers of connective tissue surrounding each nerve are:

In her ruling, she cited Jacobson v Massachusetts, a 1905 U.S. Supreme Court case that upheld the authority of U.S. states to compel people to get vaccinations. On March 25, 2020, Pritzker announced the extension of Illinois's tax filing deadline from April 15 to July 15. He also announced three new emergency assistance programs that allowed small businesses to access more than $90 million in aid. On April 23, 2020, Pritzker extended the stay-at-home order through May 29 with some modifications. Churches were prohibited from holding meetings that had more than 10 people in attendance. Some churches defied Pritzker, held meetings, and filed federal lawsuits. On May 1, 2020, Pritzker enacted a statewide mask mandate. On May 5, 2020, Pritzker announced his reopening plan, "Restore Illinois". The plan had five phases and split the state's 11 existing Emergency Medical Services Regions into four reopening regions. The regions could reopen independently of one another. All regions were then in Phase Two, which allowed retail curbside pickup and delivery along with outdoor activities such as golf, boating, and fishing. Phase Three would allow manufacturing, offices, retail, barbershops, and salons to reopen with capacity limits, along with gatherings of fewer than 10 people. In Phase 4, gatherings of up to 50 people were allowed, restaurants and bars could reopen, travel resumed, and child care and schools reopened under guidance from the IDPH. In Phase 5, the economy fully reopened.

=== Political control === The council has been under Reform UK majority control since the 2025 election. Durham was the first county council to be controlled by Labour, who took power in 1919. Between 1922 and 1925, the council was under no overall control with a Labour minority administration. From 1925 until 2021, Labour held a majority. Political control since 1919 has been as follows:

Sources: en.wikipedia.org

Reference notes

Venous access is any method used to access the bloodstream through the veins, either to administer intravenous therapy such as medication, or fluid, parenteral nutrition, to obtain blood for analysis, or to provide an access point for blood-based treatments such as dialysis or apheresis. Access is most commonly achieved via the placement of a central venous catheter, a Seldinger technique, and guidance tools such as ultrasound and fluoroscopy can also be used to assist with access location.

=== Seed === A fertilized lotus flower bears fruit that contains a cluster of 10 to 30 seeds. Each seed is ovoid 1–2.5 cm wide by 1–1.5 cm long with a brownish coat. Lotus seeds can remain viable after long periods of dormancy. In 1994, a seed from a sacred lotus, dated at roughly 1,300 years old ± 270 years, was successfully germinated. The genome of the sacred lotus was sequenced in May 2013. A dedicated genome database lists additional genome assemblies sequenced since then.

== Alkaline collagen swelling == The presence of calcium hydroxide results in the alkaline swelling of skin. The result is an influx of water into the hide/skin, and a marked increase in fibre diameter and fibre shortening. The thickness of the skin increases, but the surface area of the pelt decreases. The weight increase, owing to the uptake of water, results in a doubling of the hide/skin weight. However, this weight also needs to take into consideration that proteins (especially the hair) have been removed, and the fleshing operation is often performed after liming.

Jean becomes possessed by the Phoenix Force once more and Wolverine has no other choice but to kill her with his claws. Wolverine learns about the existence of X-23. He initially believes her to be a clone, raised to be a perfect assassin. X-23 later goes by the name Laura. She is eventually enrolled at the Xavier Institute. She quickly accepts Wolverine as a father figure, and eventually they learn that he is actually her biological father. Wolverine is brainwashed by the Hand and battles S.H.I.E.L.D., but eventually turns against them with the help of Elektra. After Scarlet Witch drastically transforms reality, Wolverine is able to recall memories of his previous life, overcoming his traumatic amnesia; he discovers that he has a son named Daken, who has been brainwashed and made a living weapon. Cyclops orders Wolverine to reform X-Force. Wolverine splits from Cyclops and opens a new school in Westchester, New York, the "Jean Grey School for Higher Learning". The Phoenix Force returns to Earth, causing conflict between the X-Men and the Avengers. Wolverine takes the side of the Avengers. Cyclops becomes possessed by the Phoenix Force and kills Professor X. A virus turns off Wolverine's healing factor. He discovers that Doctor Abraham Cornelius, the founder of the Weapon X program, has placed a bounty on his head. Wolverine gets covered in adamantium after confronting him, and dies from suffocation. Laura begins wearing a variation of Wolverine's costume and adopts his codename. Wolverine is eventually resurrected by Persephone, a mutant who can raise the dead.

=== Modern-day politicians === Janet Lynda Cheek (born 1948 in Stanley) is a politician, served as a MLA for the Stanley constituency from 1997 to 2005 and from 2009 to 2017 Mike Summers OBE (born 1952 in Stanley) is a politician, served as a MLA for the Stanley constituency from 2011 to 2017 Sharon Halford (born 1953 in Stanley) is a politician, served as a MLA for the Camp constituency from 1993 to 2001 and from 2009 until 2013 Glenn Ross (born 1964 in Stanley) is an engineer and politician, served as a MLA for the Stanley constituency from 2009 to 2011 Michael Poole (born 1984 in Falkland Islands) is a politician, served as a MLA for the Stanley constituency from 2013 to 2017 Gavin Short (born 1962 in Falkland Islands) is a politician and served as a MLA for the Stanley constituency between 2009 and 2017. He is currently a senior news reporter with FIRS and was re-elected in the 2021 elections.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

Network